Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CO NYSE:CORBF NASDAQ:MRAI NASDAQ:TRVI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOGlobal Cord Blood$0.75$1.08$2.03▼$5.50$91.16M0.16216,519 shs60 shsCORBFGlobal Cord Blood$0.55-26.7%$1.06$0.25▼$2.00$66.85M-0.52113,893 shs200 shsMRAIMarpai$1.28-6.6%$1.33$0.40▼$1.68$21.17M4.6817,380 shs16,687 shsTRVITrevi Therapeutics$6.86+0.3%$6.24$2.36▼$7.48$802.28M0.461.48 million shs2.26 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOGlobal Cord Blood0.00%+36.24%-28.57%+15.38%-37.50%CORBFGlobal Cord Blood0.00%0.00%-37.50%+15.38%-37.50%MRAIMarpai-0.72%+0.74%+5.38%+30.48%+101.47%TRVITrevi Therapeutics+1.94%+6.71%+11.76%+12.69%+140.85%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCOGlobal Cord BloodN/AN/AN/AN/AN/AN/AN/AN/ACORBFGlobal Cord BloodN/AN/AN/AN/AN/AN/AN/AN/AMRAIMarpaiN/AN/AN/AN/AN/AN/AN/AN/ATRVITrevi Therapeutics4.0468 of 5 stars4.75.00.00.03.02.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOGlobal Cord Blood 0.00N/AN/AN/ACORBFGlobal Cord Blood 0.00N/AN/AN/AMRAIMarpai 0.00N/AN/AN/ATRVITrevi Therapeutics 3.30Buy$20.88204.30% UpsideCurrent Analyst Ratings BreakdownLatest CO, CORBF, MRAI, and TRVI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2025TRVITrevi TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$25.006/2/2025TRVITrevi TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform6/2/2025TRVITrevi TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$21.005/28/2025TRVITrevi TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$21.005/20/2025TRVITrevi TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.00 ➝ $24.00(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOGlobal Cord Blood$1.24B0.07$0.18 per share4.19$6.34 per share0.12CORBFGlobal Cord Blood$196.12M0.34$0.39 per share1.40N/A∞MRAIMarpai$34.87M0.61N/AN/A($1.72) per share-0.74TRVITrevi TherapeuticsN/AN/AN/AN/A$1.30 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOGlobal Cord Blood$79.04M$0.641.17∞N/AN/AN/AN/AN/ACORBFGlobal Cord Blood$79.04MN/A0.00∞N/AN/AN/AN/AN/AMRAIMarpai-$28.75M-$1.82N/A∞N/A-85.70%N/A-100.23%8/5/2025 (Estimated)TRVITrevi Therapeutics-$47.91M-$0.45N/AN/AN/AN/A-58.41%-52.52%8/6/2025 (Estimated)Latest CO, CORBF, MRAI, and TRVI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025TRVITrevi Therapeutics-$0.10N/AN/AN/AN/AN/A5/6/2025Q1 2025TRVITrevi Therapeutics-$0.13-$0.09+$0.04-$0.09N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOGlobal Cord Blood$0.0810.67%N/A12.50%N/ACORBFGlobal Cord BloodN/AN/AN/AN/AN/AMRAIMarpaiN/AN/AN/AN/AN/ATRVITrevi TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOGlobal Cord BloodN/AN/AN/ACORBFGlobal Cord BloodN/AN/AN/AMRAIMarpaiN/A0.820.82TRVITrevi TherapeuticsN/A15.3815.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOGlobal Cord BloodN/ACORBFGlobal Cord BloodN/AMRAIMarpai49.75%TRVITrevi Therapeutics95.76%Insider OwnershipCompanyInsider OwnershipCOGlobal Cord Blood0.50%CORBFGlobal Cord Blood0.50%MRAIMarpai46.10%TRVITrevi Therapeutics18.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOGlobal Cord Blood1,202121.55 millionN/ANo DataCORBFGlobal Cord Blood1,200121.55 millionN/ANot OptionableMRAIMarpai15016.54 million5.61 millionNo DataTRVITrevi Therapeutics20117.29 million95.83 millionOptionableCO, CORBF, MRAI, and TRVI HeadlinesRecent News About These CompaniesWall Street Analysts Predict a 231.05% Upside in Trevi Therapeutics (TRVI): Here's What You Should KnowJuly 11, 2025 | zacks.comTrevi Therapeutics (NASDAQ:TRVI) Trading 6.1% Higher - Time to Buy?July 9, 2025 | marketbeat.comTrevi Therapeutics (NASDAQ:TRVI) Trading Down 3.7% - Should You Sell?July 3, 2025 | marketbeat.comAnalysts Offer Predictions for TRVI FY2025 EarningsJuly 3, 2025 | marketbeat.comCantor Fitzgerald Initiates Coverage of Trevi Therapeutics (TRVI) with Overweight RecommendationJuly 2, 2025 | msn.comTRVI Trevi Therapeutics, Inc. - Seeking AlphaJuly 1, 2025 | seekingalpha.comCantor Fitzgerald Initiates Coverage on Trevi Therapeutics (NASDAQ:TRVI)July 1, 2025 | marketbeat.comTrevi Therapeutics to Attend Leerink Partners Therapeutics Forum: I&I and MetabolismJuly 1, 2025 | prnewswire.comTRVI STOCKHOLDER ALERT: Kaskela Law LLC Announces Investigation of Trevi Therapeutics, Inc. (NASDAQ: TRVI) and Encourages Long-Term Investors to Contact the FirmJune 26, 2025 | globenewswire.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Given Consensus Recommendation of "Buy" by AnalystsJune 26, 2025 | marketbeat.comTrevi Therapeutics (NASDAQ:TRVI) Shares Down 4% - Time to Sell?June 25, 2025 | marketbeat.comTRVI - Trevi Therapeutics Inc Key Metrics - MorningstarJune 24, 2025 | morningstar.comMTrevi Therapeutics Stockholders Approve Key AmendmentsJune 17, 2025 | tipranks.comTrevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional SharesJune 5, 2025 | prnewswire.comTrevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common StockJune 3, 2025 | prnewswire.comTrevi Therapeutics Announces Proposed Public Offering of Common StockJune 2, 2025 | prnewswire.comTrevi Therapeutics Showcases Drug That Cuts Cough Frequency In Lung Disease PatientsJune 2, 2025 | benzinga.comTrevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic CoughJune 2, 2025 | prnewswire.comTrevi Therapeutics to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic CoughJune 1, 2025 | prnewswire.comH.C. Wainwright Initiates Coverage of Trevi Therapeutics (TRVI) With Buy RatingMay 29, 2025 | msn.comTrevi Therapeutics to Participate in Upcoming June ConferencesMay 29, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense3 Semiconductor Stocks Poised to Surge on AI SpendingBy Chris Markoch | June 25, 2025View 3 Semiconductor Stocks Poised to Surge on AI SpendingCO, CORBF, MRAI, and TRVI Company DescriptionsGlobal Cord Blood NYSE:CO$0.75 0.00 (0.00%) As of 07/17/2025Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants. Global Cord Blood was founded on January 17, 2008 and is headquartered in Hong Kong.Global Cord Blood NYSE:CORBF$0.55 -0.20 (-26.67%) As of 09:40 AM EasternGlobal Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2022, it operated three cord blood banks, including one in the Beijing municipality; one in the Guangdong province; and one in the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation operates as a subsidiary of Blue Ocean Structure Investment Company Ltd.Marpai NASDAQ:MRAI$1.28 -0.09 (-6.57%) As of 03:57 PM EasternMarpai, Inc., a technology-driven healthcare payer, focuses on providing services to the self-insured employer market in the United States and Israel. The company offers ancillary services, such as care management, case management, actuarial services, bill review and cost containment services. Marpai, Inc. was incorporated in 2021 and is based in Tampa, Florida.Trevi Therapeutics NASDAQ:TRVI$6.86 +0.02 (+0.29%) Closing price 04:00 PM EasternExtended Trading$6.98 +0.13 (+1.82%) As of 06:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era How Goldman Sachs Earnings Help You Strategize Your Portfolio Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
